Investors & Media

Dedicated to delivering long-term investment value.

At uniQure, the dual potential for life-changing gene therapies and long-term investor returns creates a unique—and uniquely exciting—opportunity.

Press Releases

See All

Updated stock ticker information for uniQure

(Updated every 15 minutes)

Learn More

Security and exchange commission filings for uniQure, including quarterly and annual reports

Learn More

Links to key uniQure corporate governance documents

Learn More

No webcasts scheduled. Check back soon.

March 12, 2024
Leerink Partners Global Biopharma Conference
3:40 p.m. ET - 4:10 p.m. ET
View Webcast
March 5, 2024
TD Cowen 44th Health Care Conference
Genetic Medicines Corporate Panel Discussion
2:10 p.m. ET - 3:10 p.m. ET
View Webcast
February 8, 2024
Guggenheim 6th Annual Biotechnology Conference
3:00PM-3:25PM ET
View Webcast

See All

Corporate Presentation – January 2024
View Presentation
December 2023 Huntington's Disease Program Update AMT-130 – Webcast Presentation
View Presentation
Virtual Research & Development Event – Nov. 29 event focused on preclinical gene therapy candidate for refractory temporal lobe epilepsy (rTLE) AMT-260 and uniQure AAV manufacturing advancements
View Presentation
CHDI 2022 – Radiographic and clinical progression after motor diagnosis in HD is a function of initial striatal volume and functional scores: a re-analysis of TRACK-HD/TRACK-ON HD MRI images and data
View Presentation
ESGCT 2022 – Enhancing efficacy and specificity of AAV5 capsid via small, intermediate, and large peptide insertions
View Presentation

See All